Pharmaceuticals

Purple Biotech

Purple Biotech released FY2026 Q1 earnings on May 15 (EST), actual revenue USD 0, actual EPS USD -0.184

Purple Biotech released FY2025 earnings on March 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -54.964 (forecast USD -98)

Purple Biotech released FY2025 Q4 earnings on March 13 (EST), actual revenue USD 0, actual EPS USD -19.77

Purple Biotech released FY2025 9 Months Earnings on November 14, 2025 (EST) with actual revenue of USD 0 and EPS of USD -8.544

Purple Biotech released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 0, actual EPS USD -2.86

Purple Biotech released FY2025 Semi-Annual Earnings on August 6, 2025 (EST), with actual revenue of USD 0 and EPS of USD -0.5728

Purple Biotech released FY2025 Q2 earnings on August 6 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -3.964 (forecast USD --)

Purple Biotech Ltd. Reveals New Preclinical Data

Purple Biotech Launches NT219 Phase II Clinical Study

Purple Biotech released FY2025 Q1 earnings on May 21 (EST), actual revenue USD 0, actual EPS USD -1.72

Purple Biotech Reports Positive Financial Results and Reveals CM24 Study Data

Purple Biotech Reports Q1 2025 Net Loss Narrowing to $500,000

Purple Biotech Ltd. Discloses New Data on NT219

Purple Biotech released FY2024 Q4 earnings on March 10 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.998 (forecast USD -50)

Purple Biotech released FY2024 Annual Earnings on March 10 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -44.158 (forecast USD -192)

Purple Biotech released FY2024 9 Months earnings on November 15 (EST), actual revenue USD 0, actual EPS USD -49.046

Purple Biotech released FY2024 Q3 earnings on November 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -3.826 (forecast USD -48)

Purple Biotech Ltd. Reports Positive Biomarker Results for CM24 at AACR Conference

Purple Biotech released FY2024 Q2 earnings on August 16 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -17.47 (forecast USD -31.3333)

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

PPBT

Purple Biotech reported Q1 2026 results, highlighting advancements in its CAPTN-3 platform and promising preclinical data for IM1240 against treatment-resistant tumors. The company ended the quarter with $6.4 million in cash and a modest net loss of $0.1 million. R&D expenses rose to $1.2 million, while general and administrative costs reached $1.0 million. Analysts rate PPBT stock as a Buy with a $30.00 target, though concerns about financial performance persist, leading to a Neutral rating from TipRanks’ AI Analyst.

Tip Ranks

Purple Biotech Q1 2026 Results Highlight CAPTN-3 Pivot and IM1240 Preclinical Momentum

Purple Biotech reported Q1 2026 financial results, highlighting significant anti-tumor activity from its IM1240 tri-specific antibody. The company established a Scientific Advisory Board and expanded collaboration with Converge Bio to enhance antibody development using AI. As of March 31, 2026, total cash was $6.4 million, with R&D expenses rising to $1.2 million. The adjusted operating loss was $2.1 million, while finance income increased to $2.2 million, leading to a net loss of $0.1 million.

StockTitan

Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights | PPBT Stock News

ABTS

Purple Biotech rose 7.23% in pre-market; Abits rose 7.17% in pre-market; Psyence Biomedical rose 96.84% in pre-market; Theriva Biologics rose 77.26% in pre-market; Clearmind Medicine rose 55.16% in pre-market

Price Alert

Abits

Pre-market hot trades in US stocks: Purple Biotech up 7.23% in pre-market; Abits up 7.17% in pre-market

Patent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns

Patent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns

Purple Biotech Announces CEO Transition | PPBT Stock News

Purple Biotech Announces CEO Transition  | PPBT Stock News

ACLX

BHAT

Overview of the US Stock Market The current market shows a clear trend of differentiation, with technology stocks and biotechnology stocks performing particularly well. The strong rise of Arcellx has attracted market attention, with an increase of 77.55% and significantly expanded trading volume, indicating active capital involvement. Meanwhile, Signing Day Sports also performed well, with an increase of 54.44%, achieving an astonishing rise of 315.18% in just 10 days, attracting a large amount of short-term capital. Overall, market sentiment is leaning towards active, with a noticeable increase in short-term enthusiasm. The most volatile stock in the last hour, Arcellx (ACLX), performed impressively in trading, with an increase of 77.55% and a significant increase in trading volume, showing strong capital demand. The strong performance of this stock seems to have driven the overall rise of the biotechnology sector, with market sentiment soaring. Strong stocks: 1. Guardforce AI (GFAI): up 29.02%, with significantly increased trading volume, and the market is full of expectations for its future development. 2. VenHub Global (VHUB): up 25.63%, with noticeable capital inflow and continued short-term enthusiasm. 3. Global Interactive Tech (GITS): up 22.76%, with increased recent activity attracting a lot of short-term capital

- The US stock market is currently exhibiting a clear trend of differentiation, particularly within technology and biotechnology sectors.  
- Notable performers include Arcellx, which rose by 77.55%, and Signing Day Sports, surging by 54.44%, attracting significant short-term investments.  
- Conversely, several stocks are under pressure, with Blue Hat dropping 46.28%, indicating a downturn in market sentiment.

Arcellx

Signing Day Sports

Blue Hat Interactive Ent Tech

20/20 Biolabs

Novabay Pharmac

WeShop

Gen Digital - Rights

Guardforce AI

VenHub Global

Real Messenger

Global Interactive Tech

Diginext

Clean Energy Tech

Park Ha Biological Tech

Star Fashion Culture

Planet Green

Beneficient

Lavoro

Neo-Concept

Starfighters Space

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Tandem Diabetes

Zeo Energy

Novo Nordisk AS

Algorhythm

Baiya

Antelope Enterprise

Founder

Atomera

Profusa

Homestolife

DevvStream

Knorex

Edesa Biotech

ImmunityBio

DirectBooking Tech

Oriental Culture

Interactive Strength

Critical Metals

Smart Logistics Global

Troops

Ringcentral

Planet Image

GIBO

Solana

CVRx

MongoDB

Faraday Future Intelligent Electric

Rich Sparkle

Namib Minerals

Everbright Digital

Nasus Pharma

Datadog

Cogent Communications

TRAILBLAZER MERGER CORP I USD0.0001 CL A (S/R21/04/2028)

CrowdStrike

Mangoceuticals

KLX Energy Services

DNOW

Harmony Biosciences

Zscaler

Advanced Biomed

Evolution Metals & Tech

AIOS Tech

AppLovin

Direct Digital

Snowflake

Satellogic

Brand Engagement Network

TMD Energy

Regencell Bioscience

CloudFlare

Wayfair

Apimeds Pharmaceuticals US

Anghami

XChange Tec.Inc

SABRE

Opendoor Tech Series K - CW26

N2OFF

Olenox Industries

Atlassian

Funko

NuScale Power

AST SpaceMobile

Dermata Therapeutics

Expedia

Rackspace Tech

Monday.com

Workday

Pegasystems

Shopify 

American Express

Off The Hook YS

Capital One Financial

Zoom Communications

US Stock Movement Update: Arcellx surged 77.55%, Signing Day Sports rose 54.44%, Blue Hat Interactive Ent Tech fell 46.28%

MLEC

In the past hour, the overall market in the U.S. stock market has shown a clear divergence, with technology stocks and small-cap stocks performing relatively strongly, especially the rise of individual stocks like Rackspace Tech and Purple Biotech, which has attracted considerable attention from short-term funds. Meanwhile, some cryptocurrency-related stocks such as Core Scientific and Marathon Digital have faced significant selling pressure, reflecting fluctuations in market sentiment. Overall, it seems that funds are rapidly switching between high-risk and low-risk assets, with short-term enthusiasm increasing. In the past hour, the stock with the largest movement, Rackspace Tech, rose by 9.52%, drawing strong attention in the market, and the influx of short-term funds has caused its stock price to rise rapidly, seemingly driven by optimistic expectations for its future growth potential. Strong stocks: 1. Purple Biotech: up 7.35%, with recent market expectations for its new products soaring, driving the stock price up. 2. Faraday Future Intelligent Electric: up 5.55%, as investors are confident in its future delivery capabilities amid the electric vehicle market boom. 3. BitMine Immersion Tech: despite overall market pressure, this stock still rose by 4.32%, showing that its unique market positioning has attracted funds' favor

- The U.S. stock market shows significant differentiation, with tech and small-cap stocks performing well, particularly Rackspace Tech and Purple Biotech, attracting short-term investments.  
- Conversely, some cryptocurrency-related stocks like Core Scientific and Marathon Digital faced heavy selling pressure, indicating market sentiment volatility.  
- Notable gainers included Rackspace Tech up 9.52% and Purple Biotech up 7.35%, while losers featured Moolec Science down 8.77% and Grayscale Ethereum Staking ETF down 5.29%.

Moolec Science SA

Grayscale Ethereum Staking ETF

Core Scientific, Inc.

BitMine Immersion Tech

Grayscale Bitcoin Trust BTC - ETF

Grayscale Bitcoin Mini Trust ETF

Bitfarms Canada

Galaxy Digital

Mara

Strategy

Riot Platforms

Hut 8 Mining

Coinbase

CleanSpark

Bitdeer Tech

Applied Digital

Keel Infrastructure

U.S. Stock Market Movement Update: Tech stocks are active, Rackspace Tech rises 9.52%, Moolec Science plummets 8.77%

Purple Biotech rose 7.35% in after-hours trading; Eli Lilly rose 0.04% in after-hours trading, with a transaction volume of USD 836,900; Novo Nordisk fell 0.06% in after-hours trading, with a transaction volume of USD 596,100; Pfizer rose 0.38% in after-hours trading, with a transaction volume of USD 243,000

U.S. stock night market fluctuations: Purple Biotech rose 7.35% in night trading, with clear capital flow. Can market sentiment be sustained?

Purple Biotech(PPBT.US)

Purple Biotech Q1 2026 Results Highlight CAPTN-3 Pivot and IM1240 Preclinical Momentum

Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights | PPBT Stock News

Pre-market hot trades in US stocks: Purple Biotech up 7.23% in pre-market; Abits up 7.17% in pre-market

Patent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns

Purple Biotech Announces CEO Transition | PPBT Stock News

US Stock Movement Update: Arcellx surged 77.55%, Signing Day Sports rose 54.44%, Blue Hat Interactive Ent Tech fell 46.28%

U.S. Stock Market Movement Update: Tech stocks are active, Rackspace Tech rises 9.52%, Moolec Science plummets 8.77%

U.S. stock night market fluctuations: Purple Biotech rose 7.35% in night trading, with clear capital flow. Can market sentiment be sustained?